Oxidative damage in brains of mice treated with apomorphine and its oxidized derivative

Brain Research

Volumn 992, Issue 2, 2003, Pages 246-251

  Moreira, José Cláudio F ^a   Dal Pizzol, Felipe ^a,b   Bonatto, Fernanda ^a   Da Silva, Evandro Gomes ^a   Flores, Débora G ^a   Picada, Jaqueline N ^a,c   Roesler, Rafael ^a,c   Henriques, João Antonio Pêgas ^a,c  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b UNIVERSITY OF SOUTHERN SANTA CATARINA   (Brazil)

^c UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

Author keywords

8 OSAQ; 8 oxo Apomorphine semiquinone; Antioxidant; Apomorphine; Oxidative stress

Indexed keywords

8 OXOAPOMORPHINE SEMIQUINONE; ANTIOXIDANT; APOMORPHINE; CARBONYL DERIVATIVE; CATALASE; ENZYME; FREE RADICAL; LIPID; PROTEIN; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; UNCLASSIFIED DRUG;

ANALYSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CHEMICAL PARAMETERS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DECAPITATION; ENZYME ACTIVITY; FOREBRAIN; LIPID PEROXIDATION; MALE; MOUSE; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL;

EID: 0242391811     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2003.08.051     Document Type: Article

References (32)

1. Aebi H. Catalase in vitro. Methods Enzymol. 105:1984;121-126.
2. Bannister J.V., Calaberese L. Assays for SOD. Methods Biochem. Anal. 32:1987;279-312.
3. Bindolli A., Rigobello M.P., Deeble D.J. Biochemical and toxicological properties of the oxidation products of catecholamines. Free Radic. Biol. Med. 13:1992;391-405.
4. Chen Y., Lin H., Liu J., Wan F. Potent, hydroxyl-radical-scavenging effect of apomorphine with iron and dopamine perfusion in rat striatum. Brain Res. 896:2001;165-168.
5. Davies J.A., Jackson B., Redfern P.H. The effect of amantadine, L-dopa, (plus)-amphetamine and apomorphine on the acquisition of the conditioned avoidance response. Neuropharmacology. 13:1974;199-204.
6. Deleu D., Northway M.G., Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin. Pharmacokinet. 41:2002;261-309.
7. Doyle E., Regan C.M. Cholinergic and dopaminergic agents which inhibit a passive avoidance response attenuate the paradigm-specific increases in NCAM syalilation state. J. Neural Transm., Gen. Sect. 92:1993;33-49.
8. Doyle E., O'Boyle K.M., Shiotani T., Regan C.M. Nefiracetam (DM-9384) reverses apomorphine-induced amnesia of a passive avoidance response: delayed emergence of the memory retention effects. Neurochem. Res. 21:1996;649-652.
9. Draper H.H., Hadley M. Malondialdehyde determination as index of lipid peroxidation. Methods Enzymol. 186:1990;421-431.
10. El-Bacha R.S., Netter P., Minn A. Mechanisms of apomorphine cytoxicity towards rat glioma C6 cells: protection by bovine serum albumin and formation of apomorphine-protein conjugates. Neurosci. Lett. 263:1999;25-28.
11. El-Bachá R.S., Daval J.-L., Koziel V., Netter P., Minn A. Toxic effects of apomorphine on rat cultured neurons and glial C6 cells, and protection with antioxidants. Biochem. Pharmacol. 66:2001;73-85.
12. Fernandez-Tome M.P., Sanchez-Blazquez P., del Rio J. Impairment by apomorphine of one-trial passive avoidance learning in mice: the opposing roles of the dopamine and noradrenaline systems. Psychopharmacology. 61:1979;43-47.
13. Fornai F., Battaglia G., Gesi M., Orzi F., Nicoletti F., Ruggieri S. Dose-dependent protective effects of apomorphine against methamphetamine- induced nigrostriatal damage. Brain Res. 898:2001;27-35.
14. Gassen M., Glinka Y., Pinchasi B., Youdim M.B.H. Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur. J. Pharmacol. 308:1996;219-225.
15. Gassen M., Gross A., Youdim M.B. Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine. Mov. Disord. 13:1998;661-667.
16. Graham D.G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14:1978;633-643.
17. Grunblatt E., Mandel S., Maor G., Youdim M.B. Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss. J. Neurochem. 77:2001;146-156.
18. Grunblatt E., Mandel S., Maor G., Youdim M.B. Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine. J. Neurochem. 78:2001;1-12.
19. Halliwell B., Gutteridge J.M.C. Free Radicals in Biology and Medicine. 1999;Oxford Science Publications, Oxford. 936 pp.
20. Ichihara K., Nabeshima T., Kameyama T. Opposite effects induced by low and high doses of apomorphine on passive avoidance learning in mice. Pharmacol. Biochem. Behav. 30:1988;107-113.
21. Khromov-Borisov N.N., Picada J.N., Henriques J.A.P. Dose finding in the Ames Salmonella assay. Mutat. Res. 453:2000;35-44.
22. Levine R.L., Garland D., Oliver C.N. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol. 186:1990;464-478.
23. Pardo B., Mena M.A., Casarejos M.J., Paino C.L., Garcia de Yebenes J. Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants. Brain Res. 682:1995;133-143.
24. Picada J.N., Schröder N., Izquierdo I., Henriques J.A.P., Roesler R. Differential neurobehavioral deficits induced by apomorphine and its oxidation product, 8-oxo-apomorphine-semiquinone, in rats. Eur. J. Pharmacol. 443:2002;105-111.
25. Picada J.N., Henriques J.A.P., Roesler R. An oxidized form of apomorphine fails to induce stereotypy. Schizophr. Res. 63:2003;199-200.
26. Picada J.N., Flores D.G., Zettler C.G., Marroni N.P., Roesler R., Henriques J.A.P. DNA damage in brain cells of mice treated with an oxidized form of apomorphine. Mol. Brain Res. 114:2003;80-85.
27. Picada J.N., Maris A.F., Ckless K., Salvador M., Khromov-Borisov N.N., Henriques J.A.P. Differential mutagenic, antimutagenic and cytotoxic responses induced by apomorphine and its oxidation product, 8-oxo-apomorphine-semiquinone, in bacterial and yeast. Mutat. Res. 539:2003;29-41.
28. Segura-Aguillar J., Metodiewa D., Welch C.J. Metabolic activation of dopamine o-quinones to o-semiquinones by NADPH cytochrome P450 reductase may play an important role in oxidative stress and apoptotic effects. Biochim. Biophys. Acta. 1381:1998;1-6.
29. Sit S.Y. Dopamine agonists in the treatment of Parkinson's disease - past, present and future. Curr. Pharm. Des. 6:2000;1211-1248.
30. Smythies J.R. Oxidative reactions and schizophrenia. Schizophr. Res. 24:1997;357-364.
31. Spence J.P., Jenner A., Aruoma O.I., Evans P.J., Kaur H., Dexter D.T., Jenner P., Lees A.J., Marsden D.C., Halliwell B. Intense oxidative DNA damage promoted by L-dopa and its metabolites. Implications for neurodegenerative disease. FEBS Lett. 353:1994;246-250.
32. Tsai K., Hsu T.G., Kong C.W., Lin K.C., Lu F.G. Is the endogenous peroxyl-radical scavenging capacity of plasma protective in systemic inflammatory disorders in humans? Free Radic. Biol. Med. 28:2000;926-933.